The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
SHPMY's 9-Day RSI is ranked better than 50% of 124
companies
in the Medical Distribution industry
Industry Median: 53.49
vs SHPMY: 0.02
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMY) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Shanghai Pharmaceuticals Holding Co 9-Day RSI Related Terms
SHPMY vs MCK, CAH, COR: 9-Day RSI Comparison
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co 9-Day RSI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's 9-Day RSI falls into.
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMY) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (SHPMY) has a 9-Day RSI of 0.02 as of Jul. 08, 2026. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 124 companies in the Medical Distribution industry, placing it in the top 50%.
Is Shanghai Pharmaceuticals Holding Co's 9-Day RSI too high?
Shanghai Pharmaceuticals Holding Co's current 9-Day RSI is 0.02. The Medical Distribution industry median 9-Day RSI is 53.49. Shanghai Pharmaceuticals Holding Co's value of 0.02 is 100% below this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 124 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's 9-Day RSI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 124 companies for 9-Day RSI. This puts Shanghai Pharmaceuticals Holding Co in the upper half of its industry. The industry median 9-Day RSI is 53.49. Shanghai Pharmaceuticals Holding Co's value of 0.02 is 100% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Distribution company?
The median 9-Day RSI among Medical Distribution companies is 53.49, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current 9-Day RSI of 0.02 is 100% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median 9-Day RSI is 53.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current 9-Day RSI is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (SHPMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.07, compared to a current price of $7.34 — trading 19.1% below its estimated fair value. The current 9-Day RSI is 0.02 and 100% below the Medical Distribution industry median of 53.49. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMY), the current 9-Day RSI is 0.02 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $7.34 is trading 19.1% below its estimated GF Value™ of $9.07.
GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.
Key valuation signals for SHPMY:
9-Day RSI: 0.02
GF Value™: $9.07 vs. price of $7.34 (19.1% below fair value)
Industry Position: 100% below the Medical Distribution median (#62 of 124)
No single metric tells the full story. See the SHPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
81GF Score
Get the complete analysis for SHPMY
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMY has been successfully added to your 